On June 22, 2023, Board of Directors of Regulus Therapeutics Inc. appointed Preston S. Klassen, M.D., President and Head of Research & Development, to the Board, to serve until next annual meeting of stockholders and until his successors is duly elected and qualified, or until his earlier death, resignation or removal.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.27 USD | +1.79% | -1.30% | +77.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.34% | 146M | |
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |
- Stock Market
- Equities
- RGLS Stock
- News Regulus Therapeutics Inc.
- Regulus Therapeutics Inc. Appoints Preston S. Klassen to the Board